DUBLIN, Feb. 3, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global HIV Vaccine Market & Clinical Trial Outlook 2022" report to their offering.

The Global HIV Vaccine Market & Clinical Trial Outlook 2022 report analyzes various multiple clinical and non-clinical aspects related to development of HIV vaccine worldwide. Currently there is no particular vaccine available for the treatment of HIV across the globe.

There are multiple vaccines in clinical trials for the treatment and the prevention of HIV. This report gives comprehensive clinical insight on the 65 HIV Vaccines in clinical trials and analyzes all clinical parameters involved in the development of HIV Vaccine. Report analyzes multiple approaches in the development of the HIV vaccine and lists decisive factors responsible for the commercialization of HIV vaccines.

There are also questions about how an HIV vaccine would protect the individuals and the vaccine might not be able to actually prevent the infection, but could stop or delay progression to disease, or simply reduce the infectiousness of people who do become infected with HIV. HIV prevention education and counseling are important constituents of vaccine programs and after the release of a vaccine; there will be an ongoing need for effective behavioral prevention programs.

The successful development of a preventive HIV vaccine will almost positively depend upon the involvement of both the private and public sectors from around the world. Currently, no one government or company has the resources and encouragement to take on the challenge for developing an HIV vaccine alone. Within the public sector, the development of an HIV vaccine is important for a number of different agencies, which includes the concerns in health, economic development, and international development.

Global HIV Vaccine Market & Clinical Trial Outlook 2022 Report Highlights:

- Introduction to Human Immunodeficiency Virus (HIV) Vaccines
- HIV Vaccine Development Process
- Modified Approaches for HIV Vaccine Development
- HIV Drugs Taxonomy & Resistance
- Decisive Factors for Commercialization of HIV Vaccines
- Global HIV Vaccine Clinical Pipeline by Company, Indication & Phase
- Global HIV Vaccine Clinical Pipeline:  65 Vaccines

Key Topics Covered:

1. Introduction to Human Immunodeficiency Virus (HIV) Vaccines

2. Need for the Development of HIV Vaccine

3. Primer of HIV inside the Body

4. HIV Vaccine Development Process

5. Modified Approaches for HIV Vaccine Development

6. Prophylactic & Therapeutic HIV Vaccine

7. HIV Drugs Taxonomy & Resistance

8. Decisive Factors for Commercialization of HIV Vaccines

9. Global HIV Vaccine Market Outlook

10. Global HIV Vaccine Clinical Pipeline Overview

11. Global HIV Vaccine Market Dynamics

12. Global HIV Vaccine Market Future Outlook

13. Global HIV Vaccine Clinical Pipeline by Company, Indication & Phase

14. Competitive Landscape

- AlphaVax
- Antigen Express
- Argo Therapeutics
- Bionor Pharmaceuticals
- Celldex Therapeutics
- Crucell Pharmaceutical
- FIT Biotech
- GeneCure
- Genetic Immunity
- GenVec
- GeoVax Labs
- Glaxo Smithkline
- Immune Response BioPharma
- Inovio Pharmaceuticals
- Novartis
- Oncolys Biopharma
- PaxVax
- Profectus Biosciences
- Sanofi
- TVAX Biomedical

For more information about this report visit http://www.researchandmarkets.com/research/sc57jr/global_hiv

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com

SOURCE Research and Markets